Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers
Status:
Not yet recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
Diabetic foot ulcer (DFU) is one of the most invalidating complication of diabetes and
represents a big economic burden for the society. No specific therapy is available for
diabetic foot ulcers.The aim of this study is to define a new approach for treatment of
chronic diabetic wounds. Our concept is based on the improvement of the cellular reaction to
hypoxia. It will address the transcriptional factor HIF-1 (Hypoxia inducible factor-1) which
is the cellular sensor for oxygen and which is specifically repressed by hyperglycemia. The
study will investigate the effect of local deferoxamine (0.66 mg/ml), the only known HIF-1
inducer, on the wound healing rate in patients with neuropathic diabetic foot ulcers. The
primary objective of the study will be the reduction with >50% of the wound area after 12
weeks of treatment.